PAPER Bibl M, Esselmann H, Wiltfang J

Neurochemical biomarkers in Alzheimer's disease and related disorders.

Ther Adv Neurol Disord. 2012 Nov;5(6):335-48. PubMed.

PAPER Yiannopoulou KG, Papageorgiou SG

Current and future treatments for Alzheimer's disease.

Ther Adv Neurol Disord. 2013 Jan;6(1):19-33. PubMed.

PAPER Bonini SA, Ferrari-Toninelli G, Montinaro M, Memo M

Notch signalling in adult neurons: a potential target for microtubule stabilization.

Ther Adv Neurol Disord. 2013 Nov;6(6):375-85. PubMed.

PAPER Janicki SC, Cosentino S, Louis ED

The cognitive side of essential tremor: what are the therapeutic implications?

Ther Adv Neurol Disord. 2013 Nov;6(6):353-68. PubMed.

PAPER Majláth Z, Tajti J, Vécsei L

Kynurenines and other novel therapeutic strategies in the treatment of dementia.

Ther Adv Neurol Disord. 2013 Nov;6(6):386-97. PubMed.

PAPER Jones DR, Moussaud S, McLean P

Targeting heat shock proteins to modulate α-synuclein toxicity.

Ther Adv Neurol Disord. 2014 Jan;7(1):33-51. PubMed.

PAPER Müller T, TANIMOS Study Investigators

Tolcapone addition improves Parkinson's disease associated nonmotor symptoms.

Ther Adv Neurol Disord. 2014 Mar;7(2):77-82. PubMed.

PAPER Sarva H, Henchcliffe C

Evidence for the use of pimavanserin in the treatment of Parkinson's disease psychosis.

Ther Adv Neurol Disord. 2016 Nov;9(6):462-473. Epub 2016 Oct 3 PubMed.

PAPER Dorst J, Ludolph AC, Huebers A

Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis.

Ther Adv Neurol Disord. 2018;11:1756285617734734. Epub 2017 Oct 9 PubMed.

PAPER Shin JW, Lee JM

The prospects of CRISPR-based genome engineering in the treatment of neurodegenerative disorders.

Ther Adv Neurol Disord. 2018;11:1756285617741837. Epub 2017 Nov 15 PubMed.

PAPER Wurster CD, Ludolph AC

Antisense oligonucleotides in neurological disorders.

Ther Adv Neurol Disord. 2018;11:1756286418776932. Epub 2018 May 23 PubMed.

PAPER Zhu M, Wang X, Sun L, Schultzberg M, Hjorth E

Can inflammation be resolved in Alzheimer's disease?

Ther Adv Neurol Disord. 2018;11:1756286418791107. Epub 2018 Aug 9 PubMed.

PAPER Chen SJ, Tsai HH, Tsai LK, Tang SC, Lee BC, Liu HM, Yen RF, Jeng JS

Advances in cerebral amyloid angiopathy imaging.

Ther Adv Neurol Disord. 2019;12:1756286419844113. Epub 2019 May 3 PubMed.

PAPER Gorges M, Müller HP, Liepelt-Scarfone I, Storch A, Dodel R, LANDSCAPE Consortium, Hilker-Roggendorf R, Berg D, Kunz MS, Kalbe E, Baudrexel S, Kassubek J

Structural brain signature of cognitive decline in Parkinson's disease: DTI-based evidence from the LANDSCAPE study.

Ther Adv Neurol Disord. 2019;12:1756286419843447. Epub 2019 May 16 PubMed.

PAPER Leroi I, Vatter S, Carter LA, Smith SJ, Orgeta V, Poliakoff E, Silverdale MA, Raw J, Ahearn DJ, Taylor C, Rodda J, Abdel-Ghany T, McCormick SA

Parkinson's-adapted cognitive stimulation therapy: a pilot randomized controlled clinical trial.

Ther Adv Neurol Disord. 2019;12:1756286419852217. Epub 2019 Jul 4 PubMed.